^
BIOMARKER:

ASXL1 mutation

i
Other names: ASXL1, ASXL Transcriptional Regulator 1, Additional Sex Combs Like 1, Transcriptional Regulator, Polycomb Group Protein ASXL1, Additional Sex Combs Like Transcriptional Regulator 1, Additional Sex Combs Like 1 (Drosophila), Putative Polycomb Group Protein ASXL1, Additional Sex Combs-Like Protein 1, KIAA0978, BOPS, MDS
Entrez ID:
Related biomarkers:
ASXL1 mutation
AML
venetoclax
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
ASXL1 mutation
MDS
ruxolitinib
Sensitive: A2 - Guideline
ASXL1 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
ASXL1 mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
ASXL1 mutation
AML
nivolumab
Sensitive: C3 – Early Trials
ASXL1 mutation
AML
cytarabine
Resistant: C3 – Early Trials
ASXL1 mutation
CML
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ASXL1 mutation
CML
YD312
Resistant: C3 – Early Trials
ASXL1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
ASXL1 mutation
MDS
venetoclax + azacitidine
Sensitive: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Sensitive: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Sensitive: C3 – Early Trials
ASXL1 mutation
MDS
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
ASXL1 mutation
AML
TP-0903
Resistant: D – Preclinical
ASXL1 mutation
MDS
DSP-2033
Sensitive: D – Preclinical